Drug Profile
TP 20
Alternative Names: sCR1sLexLatest Information Update: 05 Nov 2010
Price :
$50
*
At a glance
- Originator AVANT Immunotherapeutics
- Developer Celldex Therapeutics Inc
- Class Anti-ischaemics
- Mechanism of Action Complement system protein inhibitors; Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myocardial infarction; Reperfusion injury; Stroke
Most Recent Events
- 17 Jul 2003 This compound is still in active development for stroke
- 17 Jul 2003 No development reported - Preclinical for Reperfusion injury in USA (IV)
- 17 Jun 2002 This compound is still in active development for myocardial infarction